CHCWM – Cancer & Hematology Centers of West Michigan

BBI-20201001 (Bolt)

Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors